Thrombolytic therapy for central venous catheter occlusion by

Thrombolytic therapy for central venous catheter occlusion by Jacquelyn L. Baskin, Ulrike Reiss, Judith A. Wilimas, Monika L. Metzger, Raul C. Ribeiro, Ching-Hon Pui, and Scott C. Howard haematol Volume 97(5): 641 -650 May 3, 2012 © 2012 by Ferrata Storti Foundation

Diagram of the mechanism of action of thrombolytic medications. Jacquelyn L. Baskin et al. Haematologica 2012; 97: 641 -650 © 2012 by Ferrata Storti Foundation

Characteristics of thrombolytic medications. 21– 24. Jacquelyn L. Baskin et al. Haematologica 2012; 97: 641 -650 © 2012 by Ferrata Storti Foundation

Studies of thrombolytic treatment of CVC obstruction. 27– 45. Jacquelyn L. Baskin et al. Haematologica 2012; 97: 641 -650 © 2012 by Ferrata Storti Foundation

Average catheter clearance after 30 min with each of the thrombolytic medications evaluated in this study with 95% confidence intervals. Jacquelyn L. Baskin et al. Haematologica 2012; 97: 641 -650 © 2012 by Ferrata Storti Foundation

Cumulative incidence of successful catheter clearance for each of the thrombolytic medications evaluated after a maximum of 2 treatment doses, calculated as a weighted average with 95% confidence intervals. Jacquelyn L. Baskin et al. Haematologica 2012; 97: 641 -650 © 2012 by Ferrata Storti Foundation

Urokinase prophylaxis. 1, 56– 60. Jacquelyn L. Baskin et al. Haematologica 2012; 97: 641 -650 © 2012 by Ferrata Storti Foundation